Abstract
Postchemotherapy surgery for the management of advanced germ cell tumors (GCT) has evolved significantly over the past 25 years (Sheinfeld et al. 1997; Bajorin et al. 1992; Sheinfeld 2002). Prior to the utilization of platinum-based regimens, surgical debulking was followed by ineffective chemotherapy resulting in high relapse rates and poor overall survival (Merrin et al. 1977; Donohue et al. 1980). Improvements in radiographic staging, a better understanding of the role of serum tumor markers, and the introduction of cisplatinbased chemotherapy have all contributed to postchemotherapy surgery assuming a more central role in the management of patients with advanced GCT (Bosl et al. 2005; Donohue et al. 1982; Einhorn 1981; Donohue and Rowland 1984). This multimodal approach has resulted in survival rates approaching 80% in patients with advanced GCT (Sheinfeld et al. 1997; Einhorn 1981; Bosl et al. 1986).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
